KR20150050984A - Cosmetic composition and external composition comprising alkaloid for anti-inflammatory - Google Patents

Abstract

The present invention relates to an anti-inflammatory cosmetic composition or an anti-inflammatory external application composition for skin containing alkaloid as an active ingredient. The anti-inflammatory cosmetic composition or the anti-inflammatory external application composition for skin according to the present invention exhibits an excellent cyclooxygenase inhibition and inflammation inhibition effect, and is very excellent in cytotoxicity and skin safety compared with conventional anti-inflammatory agents.

Description

[0001] The present invention relates to an anti-inflammatory cosmetic composition containing an alkaloid as an active ingredient or an external composition comprising an alkaloid for anti-

The present invention relates to an anti-inflammatory cosmetic composition comprising an alkaloid as an active ingredient or an anti-inflammatory external preparation for skin.

Cosmetics are products used to protect the skin and clean the hair, but when the cosmetic composition is examined in detail, ingredients different from the purpose of skin protection are used as an indispensable substance for product formation. Examples include surfactants, preservatives, fragrances, sunscreens, pigments, and other ingredients used to impart other benefits and effects. These ingredients are generally known to cause skin irritation, rashes, edema and many other side effects (Maibach, H. I., Contact Dermatitis, 6; (1980) 369-404). In addition, sebum components, sweat components, cosmetic ingredient fatty acids, higher alcohols, proteins, etc., emitted from the body are decomposed into highly toxic substances by the skin-damaging bacteria existing on the skin, thereby causing skin inflammation . In recent years, functional cosmetics have been developed, and various functional cosmetics having various functions have been put on the market even if there are some side effects such as AHA (alpha hydroxy acid), retinol, and arbutin.

To date, substances used for antiinflammatory purposes include nonsteroidal antiinflammatory agents such as flufenamic acid, ibuprofen, benzydamine, and indomethacin, and steroids such as prednisolone and Dexamethasone, and other allantoin, azene, hydrocotizone, licorice acid, and derivatives thereof (? -Glycyrrhetinic acid, glycyrrhetinic acid derivative) New Cosmetics, Namsan, p. 162, 1993). However, the use of steroids has been limited in terms of safety to skin (Kim Chang-jong, Pathology Psychology, Hallym Company, p61-69, 1988). Indomethacin can not be used for cosmetics, The derivatives are difficult to stabilize or have poor solubility, and therefore, it is difficult to achieve a practical effect due to the limitation of the concentration when the product is actually applied.

Accordingly, it is an object of the present invention to provide a novel anti-inflammatory cosmetic composition or an anti-inflammatory external preparation for skin which is not only excellent in anti-inflammatory effect but also safe for skin, easily formable as a cosmetic composition or external preparation for skin.

As means for solving the above problems, the present invention provides an anti-inflammatory cosmetic composition comprising an alkaloid as an active ingredient or an anti-inflammatory external preparation for skin.

The alkaloid is a basic organic compound containing nitrogen and is a kind of secondary metabolites of protein amino acids and can be obtained from various biological groups including bacteria, fungi, plants and animals. Many of them have a cyclic structure such as pyridine, quinoline, isoquinoline, pyrrolidine, piperidine, indole, propane, purine, etc. Representative alkaloids include caffeine, morphine, nicotine, strychnine, atropine, cocaine, and kinin, which cause excitation of nerve tissue, heart muscle, respiratory tissue, and are mainly used as drugs and medicines. Anti-inflammation, antimicrobial and anticancer activities have been known by the effects of other alkaloids, and studies are underway.

On the other hand, the inventors of the present invention have found that alkaloids are excellent in anti-inflammatory effect and have little specific odor in the process of finding substances which are safe for skin, easily formulated into cosmetic compositions or external preparations for skin, And thus the present invention has been completed. Through the following examples, the present inventors confirmed that the alkaloid according to the present invention had excellent cyclooxygenase inhibitory effect and anti-inflammatory effect (Examples 1 and 2). It was also confirmed that skin safety to human body was excellent (Examples 3 and 4).

The alkaloid according to the present invention may be commercially available, or may be one prepared by separation, semi-synthesis or synthesis from a plant. The plant may be, but is not limited to, winter cherry (withania somnifera, ashwagandha) and green ball palm (Castanospermum austral). For example, but not limited to, the alkaloid may be isopelletierine, anaferine, or Castanospermine.

The alkaloid according to the present invention can be manufactured using a commercial product or based on known methods. The preparation of alkaloids can be varied within a range that is obvious to a person skilled in the art, and the present invention includes the scope thereof.

For example, the present invention may be those isolated and purified from plant extracts.

Extraction solvents used to extract alkaloids from plants include, but are not limited to, solvents selected from water, organic solvents or mixtures thereof. The organic solvent may be a polar solvent such as an alcohol having 1 to 5 carbon atoms, ethyl acetate or acetone, a non-polar solvent such as ether, chloroform, benzene, hexane or dichloromethane, or a mixture thereof. For example, the alcohol having 1 to 5 carbon atoms may be selected from methanol, ethanol, propanol, butanol or isopropanol.

In addition, the alkaloid according to the present invention may be a fraction obtained by further fractionating the primary extract extracted using the extraction solvent with an extraction solvent having a different polarity. For example, solvents with different polarity may be ether, benzene or hexane.

Two or more kinds of solvents may be used for the fractionation, and the solvent extracts may be sequentially used or mixed according to the polarity of the solvent, but not limited thereto.

The thus-prepared extract or the fraction obtained by performing the fractionation process can then separate and purify the active ingredient according to a conventional separation and purification method. But is not limited to, high performance liquid chromatography (HPLC) can be used.

The alkaloid prepared by the above method may be in the form of a salt. The salt may be an acid addition salt formed using an organic acid or an inorganic acid, and the organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid , Succinic acid, succinic monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, gluconic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxyacetic acid, benzenesulfonic acid, Methanesulfonic acid-based salts, and methanesulfonic acid-based salts. The inorganic acid may be at least one selected from the group consisting of hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid and boric acid-based salts. Preferably in the hydrochloride or acetate form, more preferably in the hydrochloride form.

Separately, additionally saltable forms include, but are not limited to, the salts of gabapentin, gabapentin, pregabalin, nicotinate, adipate, hemimarate, cysteine, acetylcysteine, methionine, arginine, lysine, Aspartate and the like.

In the present invention, the term "inflammation" means a phenomenon appearing for a series of defensive purposes for minimizing the reaction of a cell or a tissue caused by any cause and restoring the damaged region to the original state. , Body fluid reaction, and cell reaction, resulting in pain, edema, redness, fever, etc., resulting in dysfunction. The disease caused by inflammation may be at least one selected from the group consisting of various dermatitis, allergies, systemic lupus erythematosus, retinitis, gastritis, hepatitis, enteritis, pancreatitis and nephritis. The allergies include anaphylaxis, allergic rhinitis allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria, insect allergies, food allergies and drug allergies.

The inflammation is caused by various biochemical phenomena in vivo. In particular, the inflammation is caused by an enzyme involved in biosynthesis of prostaglandin from arachidonic acid, such as cyclooxygenase (COX) and L-arginine (L- It is known that nitric oxide synthase (NOS), an enzyme that produces nitric oxide (NO) from arginine, plays an important role in mediating the inflammatory response.

The term " prostaglandin (PG) "in the present invention is a kind of physiologically active hormone synthesized in the body and has a function of regulating the inflammatory reaction. The prostaglandins are classified into PG1, PG2 and PG3, PG1 and PG3 inhibit inflammation, and PG2 induce inflammation. The prostaglandin is biosynthesized through cyclooxygenase (COX) using arachidonic acid as a precursor.

The term "cyclooxygenase (COX)" in the present invention is an enzyme that catalyzes the first step of the synthesis of prostaglandin, wherein two molecules of oxygen are introduced into arachidonic acid to synthesize PG2, and prostaglandin endoperox It is also called seed synthase. Cyclooxygenase-1 (COX-1), which is always present in cells, contains prostaglandins (PGs) required for cytoprotective action, while cyclooxygenase COX-2 is known to play an important role in the inflammatory response by increasing rapidly in the cell during the inflammatory reaction.

The term "nitric oxide (NO)" in the present invention is caused by various cytokines or iNOS induced by external stimuli, and is known to cause cytotoxicity or various inflammatory responses. Chronic inflammation is also known to be associated with increased iNOS activity (Appleton L. et al. Pharmacol., 35. 27-28.1996).

The alkaloids according to the present invention have a cyclooxygenase (COX) inhibitory activity, and are thus particularly effective for inflammation mediated by biosynthesis of prostaglandins.

The anti-inflammatory composition of the present invention can provide a desirable anti-inflammatory effect when it contains an effective amount of alkaloid. In the present invention, "effective amount" means an amount capable of exhibiting sufficient cyclooxygenase (COX) inhibitory activity. For example, the effective amount of the alkaloid contained in the anti-inflammatory composition of the present invention may be 0.001 to 20 parts by weight based on 100 parts by weight of the total composition. For example, 0.001 to 10 parts by weight, 0.01 to 20 parts by weight, 0.01 to 10 parts by weight, and 0.1 to 10 parts by weight. If the alkaloid is contained in an amount of less than 0.001 part by weight, a sufficient anti-inflammatory effect can not be expected. If the alkaloid is contained in an amount exceeding 20 parts by weight, an unwanted reaction such as allergy may occur or there may be a problem in skin safety. will be. The composition is not necessarily limited to this, and may vary depending on the purpose of the composition, the form of the composition, and the condition of the applicant.

On the other hand, the composition of the present invention may contain one or more components which exhibit a known anti-inflammatory effect or a component that enhances the anti-inflammatory effect.

If the additional anti-inflammatory component is included, the anti-inflammatory effect of the present invention can be further enhanced. As anti-inflammatory ingredients known in the art, ibuprofen, flufenamic acid or indomethacin in a non-steroid system, prednisolone or dexamethasone in a steroid system, other allantoin, , Hydrocortisone, licorice acid, and derivatives thereof. The additional anti-inflammatory component includes all of the above-listed components and analogs thereof exhibiting an equivalent effect thereto. In addition, as a known anti-inflammatory component which can be used in cosmetic compositions, there may be mentioned hyaluronic acid, Daphnetin, Glycyrrhizin, Quercetin, Rosmarinic acid, Madecassic acid, Carmine julren (Chamazulene), Baikal lane (Bicalein), the emodine (Emodin), astaxanthin (astaxanthin), Nord bereuge Nin (norbergenin), 4-O- methyl hono kiol (4-O-methylhonokiol), poly datin ( polydatin, ferulic acid, 2-methoxycinnamaldehyde, 2,4-dihydroxyacetophenone, terpinen-4-ol, ol, and derivatives thereof. The present invention is further illustrated by the following examples. The additional anti-inflammatory component may include all of the analogues and plant extracts exhibiting the same effects as those listed above.

The added components may be contained in an amount of 0.0001 to 10 parts by weight based on 100 parts by weight of the total composition. The content of the added components may vary according to requirements such as the activity of cyclooxygenase (COX), skin safety, It can be adjusted.

The cosmetic composition or external preparation for skin according to the present invention can be formulated by a conventional method. For formulation into a skin external preparation, reference may be made to the contents disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, and International Cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995, which is incorporated herein by reference in its entirety. Which are incorporated herein by reference.

The cosmetic composition may be prepared in the form of a general emulsified formulation and a solubilized formulation. For example, lotion such as soft lotion or nutrition lotion; Lotion such as facial lotion, body lotion; Nourishing cream, moisture cream, cream such as eye cream; essence; Makeup ointment; spray; Gel; pack; Sunscreen; Makeup base; A foundation such as a liquid type, a solid type or a spray type; powder; Make-up removers such as cleansing creams, cleansing lotions and cleansing oils; Or cleansing agents such as cleansing foams, soaps, bodywashes, and the like. The external preparation for skin may have a formulation such as, but not limited to, ointments, patches, gels, creams or sprays.

The content of the active ingredient may be varied according to the formulation. For example, the cosmetic composition may contain a relatively high concentration of the alkaloid in the case of a wash-off type cosmetic such as a make-up removing agent, a detergent or the like in which the active ingredient remains on the skin in a short period of time. On the other hand, leave-on type cosmetics such as cosmetics, milky lotions, creams, and essences whose effective ingredients stay on the skin for a long period of time may contain lower alkaloids than wash-off type cosmetics will be.

In addition, it may further include adjuvants or carriers such as stabilizers, solubilizers, vitamins, pigments or fragrances which are conventionally used in cosmetic compositions or external skin preparations. A surfactant, a water, an ionic or nonionic emulsifier, a filler, a metal, or a combination thereof. The present invention also relates to the use of the above- A cosmetic field such as an ionic sequestering and chelating agent, a preservative, a vitamin, a barrier, a wetting agent, a essential oil, a dye, a pigment, a hydrophilic or lipophilic active agent, a lipid vesicle and any other ingredient commonly used in cosmetic or dermatological applications, May contain adjuvants conventionally used in the field of dermatology. The components can also be introduced in amounts commonly used in the cosmetics field or the skin science field.

The alkaloids according to the present invention exhibit excellent cyclooxygenase (COX) inhibition and inflammation inhibitory effects, and are superior in cytotoxicity and skin safety to the conventional anti-inflammatory agents.

Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments and preparations which will be described in detail below. However, it should be understood that the present invention is not limited to the embodiments and manufacturing examples described below, but may be embodied in many different forms and should not be construed as being limited to the exemplary embodiments set forth herein. It is provided to inform the person completely of the scope of the invention.

[Example 1]

Cyclooxygenase (COX) inhibitory effect

In the present invention, cyclooxygenase (COX) was extracted from sheep seminal vesicles of Pel-Freeze. The cyclooxygenase (COX) according to the present invention was prepared by crushing the two hypocotyls and then centrifuging at 3000 rpm for 10 minutes to take up the supernatant. The supernatant was centrifuged at 10000 rpm for 1 hour to separate precipitates, (0.1 M, pH 8.0).

25 μg of hemoglobin is added to 100 mL of Tris buffer solution (0.1 M, pH 8.0) to make a substrate to be 1.1 mM arachidonic acid, and then 10 μl of 10,000 units of cyclooxygenase is added to the substrate. After adding 0.5 ppm, 10 ppm and 50 ppm of isopelletriene, anapelin or carnano-spermin, respectively, the initial oxygen consumption was measured with a measuring device (Yellow Spring Instrument company, Model 53 oxygen monitor) to measure the cyclooxygenase activity Respectively. The results are shown in Table 1 below.

Inhibition rate (%) 0.5 ppm 10 ppm 50 ppm (w / w) Isopeletriene 24 ± 2 29 ± 3 44 ± 4 Anapelin 26 ± 2 34 ± 4 48 ± 2 Carnano-spermine 30 ± 2 38 ± 5 51 ± 5

n = 3

As shown in Table 1, it was confirmed that 44 ppm of isopelletriene, 48 percent of anapelin, and 51 percent of castanospermine had an inhibitory effect on cyclooxygenase at 50 ppm, compared with the negative control.

[Example 2]

Anti-inflammatory effect test

(A. Crummey, GP Harper, EA Boyle and FR Mangan. Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compounds. Agents and Actions 1987: 20: 69 -76) was used to examine the anti-inflammatory effect.

A total of 8 sets of 7 hairless mice (7 mice) were prepared, and both ears of the mice were thoroughly washed with ethanol, and the thickness was measured using a micrometer. A control group coated with a sample containing 1 ppm or 10 ppm of isopelletriene, anapelin or carnanoferrin, a control group containing 1 ppm of indomethacin, and a control group coated with ethanol.

The right ear of the mouse was coated with 2 mg / ear of arachidonic acid to induce inflammation, and the left ear was coated with ethanol to examine the degree of inflammation caused by the sample itself. The sample group contained 1 ppm and 10 ppm of isopelletiene, anapelin or carnano-spermin, respectively. The control group contained 1 ppm of indomethacin, and the control group was 20 minutes of ethanol. ≪ / RTI > in each ear for 4 days. The degree of edema of both ears was measured repeatedly three times for each ear using a micrometer.

Table 2 shows the inhibition rates of swelling of the samples against the control (ethanol), and the inhibition rates of swelling against the comparative group (indomethacin) are shown in Table 3.

sample density Glume (㎛) Decrease (%) Before sample treatment After sample treatment Sample group Isopeletriene 1 ppm 324 512 33.1 10 ppm 325 503 36.7  Anapelin 1 ppm 323 513 32.3 10 ppm 324 508 34.5 Carnano-spermine 1 ppm 322 506 34.5 10 ppm 323 495 38.9 Comparative group Indomethacin 1.0 325 452 54.8 Control group Arachidonic acid 2mg / ear 321 602

※ Inhibition rate (%) = (AB) / A × 100

   A: Mean thickness change of the control ear

       (Thickness of ear treated with arachidonic acid - thickness of untreated ear)

   B: Mean thickness change of sample application group ear

       (Thickness of sample treated ear - thickness of untreated ear)

Inhibition rate (%) compared to the control group (indomethacin) 1 ppm 10 ppm Isopeletriene 60% 67% Anapelin 59% 63% Carnano-spermine 63% 71%

As shown in Table 2, the degree of inflammation was as high as 36.7% for isopellitriane, 34.5% for anapelin and 38.9% for carthanospermine at 10 ppm. In addition, as shown in Table 3, the anti-inflammatory effect of isopeletiene 67%, anapelin 63%, and carnano-spermine was superior to indomethacin at 10 ppm.

On the other hand, when verifying the significant difference in the rate of edema growth, isopeletriene, anapelin or carnano-spermine showed 99% significant difference with arachidonic acid.

[Example 3]

The first human stimulation test (Human patch test)

The first human stimulation test was conducted on 50 healthy adult men and women according to the CTFA guidelines (The Cosmetic, Toiletry and Fragrance Association, Inc., Washington, DC, 20036, 1991). A sample containing 50 ppm each of isopelletin, anapelin or carnenoprecamine, 1.0% sodium lauryl sulfate and 10% ethanol, a sample containing 1.0% sodium lauryl sulfate and 10% ethanol, and 10% Was used as a sample to evaluate human irritation. Each of the samples was dropped in a Finn chamber (20 占 퐇 each), and the sample was placed on the back of the human body to be tested and fixed with a tape. After 24 hours of application, the patches were removed. After 4 hours from the removal of the patches, the skin reaction of the test site was judged according to the following criteria, and the results are shown in Table 4.

    <Criteria>

     -: No erythema or unusual phenomenon

      ±: slightly redder than around

      +: Significantly reddened than surrounding

    ++: More reddening and swelling than the surrounding area

The number of subjects to be tested is expressed by the following formula: Number of stimuli = [{(占) number 占 1} + {占 number 占 2} + {

sample Number of subjects Judgment result Irritation degree ++ + ± - Isopelletriene (50 ppm),
Sodium lauryl sulfate (1%),
Ethanol (10%) 50 - - 4 46 0.08 Anapelin (50 ppm),
Sodium lauryl sulfate (1%),
Ethanol (10%) 50 - - 5 45 0.10 Carnano-sipper (50 ppm),
Sodium lauryl sulfate (1%),
Ethanol (10%) 50 - - 6 44 0.12 Sodium lauryl sulfate (1%) 50 2 8 10 30 0.60 Ethanol (10%) 50 - - 10 40 0.20

As can be seen in Table 4 above, isopeletierein, anapherin and carnano-spermine significantly alleviated the stimulation of sodium lauryl sulfate and ethanol. These results are believed to be attributable to the excellent anti-inflammatory effect as shown in the anti-inflammatory effect test described above. Thus, it can be seen that isopeletielin, anapelin, or castanospermine according to the present invention is a skin-safe ingredient .

[Example 4]

Anti-inflammatory sensory test for human body

Ten subjects were randomly assigned to receive 50 ppm of isopelletirin, anapelin, and carnano-spermine twice a day for 7 days. Water was used as a control.

The sample (50 ppm) Effective (persons) No change (persons) Isopeletriene 7 3 Anapelin 8 2 Carnano-spermine 7 3 water 2 8

As can be seen in Table 5 above, isopeletriene, anapherin, and carnano-spermine effectively relieve rashes. These results are believed to be attributable to their excellent anti-inflammatory effect as shown in the anti-inflammatory effect test described above. Thus, it was confirmed that isopeletielin, anapherin, and carnano-spermine according to the present invention are safe ingredients for skin .

Hereinafter, the preparation examples (formulation examples) of the cosmetic composition of the present invention are presented, but the following production examples are illustrative of the composition of the present invention, but are not limited thereto.

[Manufacturing Example]

The formulations of Preparation Examples 1 to 6 were prepared using conventional methods according to the following composition.

[Production Example 1]

toilet water

Raw material wt% (w / w)

Glycerin 5.0

Dipropylene glycol 3.0

Hyaluronic acid 0.5

Polyoxyethylene 0.1

Hardened castor oil 0.1

Polyethylene oleyl ethyl ethanol 5.0

Preservative 0.15

Fragrance quantity

Pigment amount

The compound of formula 1 0.1

Purified water to 100

[Production Example 2]

essence

Raw material wt% (w / w)

Cetostearyl alcohol 1.0

Self-emulsifying monostearic acid 1.0

Wax 0.5

Squalane 5.0

Isocetyl octanoate 3.0

Dimethylsiloxane 0.3

Sorbitan monostearate 0.5

Polyethylene glycol monostearate 8.0

Glycerin 4.0

Propylene glycol 0.2

Carboxy polymer 0.22

Triethanolamine 0.25

Antiseptic

Fragrance quantity

Pigment amount

Compound of Formula 1 7.0

Purified water to 100

[Production Example 3]

Lotion

Raw material wt% (w / w)

Cetostearyl alcohol 0.8

Self emulsifying monostearic acid 10

Wax 0.5

Stearic acid 0.5

Liquid paraffin 7.0

Squalane 5.0

Macadamia Oil 3.0

Isocetyl octanoate 2.0

Dimethylsiloxane 0.3

Sorbitan monostearate 0.5

Polyethylene glycol monostearate 1.2

Glycerin 4.0

Propylene glycol 4.0

Betain 4.0

Carboxy polymer 0.12

Triethanolamine 0.15

Preservative 0.25

Fragrance quantity

Pigment amount

Compounds of Formula 1 5.0

Purified water to 100

[Production Example 4]

cream

Raw material wt% (w / w)

Cetostearyl alcohol 3.0

Self emulsifying monostearic acid 1.5

Chin type monostearate 1.5

Wax 0.5

Liquid paraffin 8.0

Squalane 7.0

Isocetyl octanoate 4.0

Tablet Jojoba 4.0

Dimethylsiloxane 0.3

Monostearic acid sorbitan 1.0

Polyethylene glycol monostearate 1.2

Glycerin 6.0

Propylene glycol 4.0

Betain 4.0

Xanthan gum 0.06

Triethanolamine 0.10

Preservative 0.25

Fragrance quantity

Pigment amount

Compound of Formula 1 7.0

Purified water to 100

[Production Example 5]

Gel

Raw material wt% (w / w)

Glycerin 4.0

Propylene glycol 4.0

Ethanol 10

Polyoxyethylene hydrogenated castor oil 0.1

Carboxy polymer 0.30

Triethanolamine 0.30

Antiseptic

Fragrance quantity

Pigment amount

Compound of Formula 1 1.0

Purified water to 100

[Production Example 6]

Ointment

Raw material wt% (w / w)

Cetostearyl alcohol 2.0

Self emulsifying type monostearic acid 2.0

Stearic acid 1.0

Beeswax 4.0

Squalane 7.0

Monostearin glycerin 3.0

Monostearic acid sorbitan 1.0

Polysorbate 80 3.0

Glycerin 5.0

Propylene glycol 4.0

Fragrance quantity

Pigment amount

Compound 10.0

Vaseline to 100

Claims (12)

An anti-inflammatory cosmetic composition comprising an alkaloid as an active ingredient.
The method according to claim 1,
Wherein the alkaloid is an extract isolated from a plant or obtained through synthesis or semisynthetic.
3. The method of claim 2,
Wherein said plant is at least one selected from the group consisting of winter cherry (Withania somnifera) and green ball palm (Castanospermum austral).
The method according to claim 1,
Wherein the alkaloid is at least one selected from the group consisting of isopelletierine, anaferine, and castanospermine.
The method according to claim 1,
Wherein the alkaloid is contained in an amount of 0.001 to 20 parts by weight based on 100 parts by weight of the total cosmetic composition.
The method according to claim 1,
Wherein the anti-inflammatory cosmetic composition has a formulation selected from the group consisting of lotion, milky lotion, cream, essence, cosmetic lotion, spray, gel, pack, sunscreen, makeup base, foundation, powder and detergent.
An anti-inflammatory dermatological agent containing an alkaloid as an active ingredient.
8. The method of claim 7,
Wherein the alkaloid is an extract isolated from a plant or obtained through synthesis or semisynthetic.
9. The method of claim 8,
Wherein said plant is at least one selected from the group consisting of winter cherry (Withania somnifera) and green ball palm (Castanospermum austral).
8. The method of claim 7,
Wherein the alkaloid is at least one selected from the group consisting of isopelletierine, anaferine and castanospermine.
8. The method of claim 7,
Wherein the alkaloid is contained in an amount of 0.001 to 20 parts by weight based on 100 parts by weight of the total composition.
8. The method of claim 7,
Wherein the external preparation for skin has a formulation selected from the group consisting of ointments, patches, gels, creams or sprays.